Skip to main content

DUBLIN–(BUSINESS WIRE)–The “Antibody-Drug Conjugates Market Size, Share and Trend Analysis Report by Application (Blood Cancer, Breast Cancer, Urothelial/Bladder Cancer), By Technology (Cleavable Linker , non-cleavable, unlinked) and segment forecast, 2022-2030 report” has been added to from offer.

The global market size of antibody-drug conjugates is expected to reach over USD 22.87 billion by 2030, registering a CAGR of 16.4%

The presence of strong pipeline products and strategic initiatives undertaken by major players are expected to boost the market growth over the forecast period.

Key players such as ADC Therapeutics, Seagen. Inc., Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., AstraZeneca, Daiichi Sankyo and others collaborate to develop and commercialize products.

For example, in February 2022, Mersana Therapeutics partnered with Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson Inc., for the research and development of new ADCs to treat various cancers. As part of the agreement, Janssen will pay Mersana Therapeutics $40.0 million upfront and potentially more than $1.0 billion in milestone payments for the development of new ADCs.

Extensive research and growing funding for the development of new antibody-drug conjugates by pharmaceutical companies is expected to boost the market growth. For example, in April 2021, Adcendo and Adcentrx, two new startups raised approximately $112.0 million for the development of ADC with their novel approach to cancer treatment.

Adcendo has raised $51.0 million for the development of novel ADCs targeting endocytic receptors, which act as the drug delivery organism. Adcentrx has raised $50.0 million for its ADC research programs.

Strict reimbursement policies for ADCs may restrain the market growth owing to the high cost associated with treating ADCs as compared to alternative conventional treatments such as monoclonal antibody therapy and chemotherapy. This higher cost of treatment should hamper reimbursement coverage.

For example, in February 2020, the National Center for Pharmaco Economics, Ireland, issued a negative opinion on Roche’s Kadcyla (trastuzumab emtansine) for reimbursement due to its low cost-effectiveness.

Rising geriatric population coupled with growing prevalence of diseases such as multiple myeloma (MM) is expected to drive the demand for ADCs, thereby driving the growth of the market over the forecast period. Multiple myeloma (MM) is a disease of the aging population, and nearly 30,000 new cases of MM were diagnosed in 2021.

The median age of patients diagnosed with multiple myeloma is 70 years old. Thus, the introduction of new ADCs for the treatment of multiple myeloma is expected to drive the market growth. For example, in August 2020, the FDA approved GlaxoSmithKline’s BLENREP as a monotherapy to treat relapsed or refractory multiple myeloma. Blenrep was the first anti-BCMA therapy approved for the treatment of multiple myeloma.

Highlights of the Antibody Conjugates Market Report

  • Breast cancer dominated the market in 2021, owing to the high prevalence of breast cancer and the availability of several ADC products for the treatment of breast cancer.

  • The cleavable linker segment dominated the market in 2021 owing to the increasing adoption of cleavable linker technology in commercial ADC products and the advantages associated with the use of cleavable linker over other linker technologies.

  • North America dominated the market in 2021 owing to the presence of key pharmaceutical companies such as Pfizer, Inc., Gilead Life Sciences, Inc., and Seagen, Inc. and their strategic initiatives for the development of new ADCs.

Industry Outlook

Driver impact analysis

  • Presence of a strong product pipeline

  • Growth of the geriatric population

  • Increase in cancer incidence and prevalence

Market Restriction Analysis

  • High manufacturing costs and downstream processing challenges for ADCs

  • Strict refund policies for ADCs

Mapping penetration and growth prospects

SWOT analysis ; by factor (political and legal, economic and technological)

Porter’s Five Forces Analysis

Pipeline analysis

Company Profiles

  • Takeda Pharmaceutical Company Limited

  • F. Hoffmann-La Roche Ltd.

  • Pfizer, Inc.

  • Astrazeneca

  • Gilead Sciences, Inc.

  • Astellas Pharma, Inc.

  • Seagen, Inc.

  • Daiichi Sankyo Company, Limited

  • GlaxoSmithKline plc

  • Adc Therapeutic Saa

For more information about this report, visit